Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Cryselda Trevino

Physician Assistant Rockwall, TX Physician Assistant

NPI 1982243663 CMS profile 10714688

2265 N Lakeshore Dr Ste 101, Rockwall, TX 75087

Open in the dashboard

General payments

$8,827

402 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Cryselda Trevino of Rockwall, TX is reported in the CMS Open Payments database as having received $8,827 across 402 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,163 96
2024 General $1,690 92
2023 General $914 52
2022 General $961 57
2021 General $3,098 105

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Cryselda Trevino
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Cryselda Trevino were reported at $2,163. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Cryselda Trevino Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $3,098 $132 $37–$438 $132
2022 $961 $155 $48–$522 $149
2023 $914 $167 $52–$557 $160
2024 $1,690 $178 $55–$600 $164
2025 $2,163 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Biohaven Pharmaceuticals, Inc. $1,569 13 payments
  2. AbbVie, Inc. $1,042 66 payments
  3. Lilly USA, LLC $632 41 payments
  4. AstraZeneca Pharmaceuticals LP $522 27 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $517 23 payments
  6. Novo Nordisk Inc $516 29 payments
  7. Pfizer Inc. $494 25 payments
  8. GlaxoSmithKline, LLC. $441 27 payments
  9. Amgen Inc. $392 18 payments
  10. Merck Sharp & Dohme Corporation $278 11 payments
  11. Other $2,422 122 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $7,627 401 payments
  2. Consulting Fee $1,200 1 payment
Products named General payments · program years 2021–2025
  1. NURTEC ODT Primary Care $1,646 18 payments
  2. VRAYLAR $564 33 payments
  3. TRELEGY ELLIPTA $359 22 payments
  4. Ozempic $325 19 payments
  5. FARXIGA $323 17 payments
  6. RYBELSUS $320 18 payments
  7. NURTEC ODT Pain $280 15 payments
  8. JARDIANCE Diabetes $274 11 payments
  9. JARDIANCE Diabetes $274 16 payments
  10. MOUNJARO $213 13 payments
  11. Other $6,450 347 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 120 drugs

Part D claims

5,021

Median for Physician Assistant: 241

Drug cost

$468,051

Median for Physician Assistant: $4,110

Branded share of claims

20%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 80 $100,416
Ozempic Semaglutide Brand 77 $77,120
Jardiance Empagliflozin Brand 56 $64,831
Trulicity Dulaglutide Brand 29 $43,006
Eliquis Apixaban Brand 29 $28,958
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 33 $22,437
Myrbetriq Mirabegron Brand 27 $21,551
Linzess Linaclotide Brand 17 $20,214
Toujeo Max Solostar Insulin Glargine,hum.Rec.Anlog Brand 13 $11,249
Entresto Sacubitril/Valsartan Brand 12 $9,727

The 10 drugs with the highest cost, of 120 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 24 billing codes

Paid by Medicare

$34,396

Of which drugs: $7,067

Medicare patients

190

Average age 74

Services billed

932

114 women, 76 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 74%
Arthritis 46%
Diabetes 29%
COPD 23%
Ischemic heart disease 22%
Chronic kidney disease 17%
Depression 17%
Cancer 13%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 12 12 $3,487
Vaccine for influenza for injection into muscle 90662 Office 38 38 $3,079
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 20 92 $51
Injection, ceftriaxone sodium, per 250 mg J0696 Office 11 26 $7
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 20 92 $6

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 34 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $171
  • Lilly USA, LLC $64
$235 56 —
VRAYLAR
  • AbbVie, Inc. $180
$180 — —
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $99
$99 — —
NUZYRA
  • Paratek Pharmaceuticals, Inc. $70
$70 — —
NURTEC ODT
  • PFIZER INC. $67
$67 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 34 with Patron

Records

402 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record